Free Trial

Galera Therapeutics (GRTX) Competitors

Galera Therapeutics logo
$0.02 0.00 (-4.12%)
As of 03:41 PM Eastern

GRTX vs. TRAW, OMGA, INDP, GNPX, AIM, CHRO, BFRI, ALBT, SNGX, and AEZS

Should you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include Traws Pharma (TRAW), Omega Therapeutics (OMGA), Indaptus Therapeutics (INDP), Genprex (GNPX), AIM ImmunoTech (AIM), Chromocell Therapeutics (CHRO), Biofrontera (BFRI), Avalon GloboCare (ALBT), Soligenix (SNGX), and Aeterna Zentaris (AEZS). These companies are all part of the "pharmaceutical products" industry.

Galera Therapeutics vs.

Galera Therapeutics (NASDAQ:GRTX) and Traws Pharma (NASDAQ:TRAW) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, community ranking, dividends, risk and analyst recommendations.

Galera Therapeutics has a net margin of 0.00% compared to Traws Pharma's net margin of -62,294.25%.

Company Net Margins Return on Equity Return on Assets
Galera TherapeuticsN/A N/A -99.34%
Traws Pharma -62,294.25%N/A -822.38%

Traws Pharma has higher revenue and earnings than Galera Therapeutics. Galera Therapeutics is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galera TherapeuticsN/AN/A-$59.08M-$0.35-0.07
Traws Pharma$226K29.74-$18.95M-$32.81-0.04

Galera Therapeutics received 50 more outperform votes than Traws Pharma when rated by MarketBeat users.

CompanyUnderperformOutperform
Galera TherapeuticsOutperform Votes
50
54.35%
Underperform Votes
42
45.65%
Traws PharmaN/AN/A

50.8% of Galera Therapeutics shares are held by institutional investors. Comparatively, 7.9% of Traws Pharma shares are held by institutional investors. 12.9% of Galera Therapeutics shares are held by company insiders. Comparatively, 13.6% of Traws Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Galera Therapeutics has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Traws Pharma has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500.

In the previous week, Traws Pharma had 2 more articles in the media than Galera Therapeutics. MarketBeat recorded 2 mentions for Traws Pharma and 0 mentions for Galera Therapeutics. Traws Pharma's average media sentiment score of 0.96 beat Galera Therapeutics' score of 0.00 indicating that Traws Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
Galera Therapeutics Neutral
Traws Pharma Positive

Summary

Galera Therapeutics and Traws Pharma tied by winning 6 of the 12 factors compared between the two stocks.

Get Galera Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRTX vs. The Competition

MetricGalera TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.76M$6.50B$5.34B$8.42B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-0.079.1526.8519.72
Price / SalesN/A252.36387.23121.26
Price / CashN/A65.8538.2534.62
Price / Book-0.016.456.774.51
Net Income-$59.08M$144.21M$3.23B$248.32M
7 Day PerformanceN/A2.38%1.81%0.60%
1 Month PerformanceN/A4.50%10.93%13.18%
1 Year PerformanceN/A-2.75%17.15%7.39%

Galera Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRTX
Galera Therapeutics
N/A$0.02
-4.1%
N/A-87.2%$1.76MN/A-0.0730
TRAW
Traws Pharma
1.0005 of 5 stars
$1.39
+4.5%
N/AN/A$7.09M$226,000.00-0.0117Positive News
Earnings Report
Gap Up
OMGA
Omega Therapeutics
2.2977 of 5 stars
$0.13
-21.8%
$9.20
+7,260.0%
-94.3%$6.92M$8.10M-0.09120News Coverage
Gap Up
INDP
Indaptus Therapeutics
2.7076 of 5 stars
$0.42
+3.9%
$8.50
+1,941.8%
-83.8%$6.68MN/A-0.246Gap Down
GNPX
Genprex
0.9034 of 5 stars
$0.28
-3.3%
$10.00
+3,523.2%
-88.2%$6.67MN/A0.0020
AIM
AIM ImmunoTech
1.4317 of 5 stars
$0.09
-22.3%
$2.75
+2,908.8%
-77.7%$6.61M$170,000.00-0.1920Gap Down
High Trading Volume
CHRO
Chromocell Therapeutics
N/A$1.08
-1.9%
N/A-46.8%$6.59MN/A-0.734Gap Down
BFRI
Biofrontera
2.6785 of 5 stars
$0.68
-1.8%
$7.00
+925.6%
-42.1%$6.45M$37.32M-0.3070Earnings Report
Analyst Forecast
Analyst Revision
Gap Up
ALBT
Avalon GloboCare
0.567 of 5 stars
$3.87
-0.5%
N/A-11.0%$6.39M$1.33M-0.195Positive News
Upcoming Earnings
SNGX
Soligenix
0.9773 of 5 stars
$1.96
-1.3%
N/A-68.8%$6.38M$840,000.00-0.2620
AEZS
Aeterna Zentaris
N/A$3.55
+5.0%
N/A-57.0%$6.37M$2.37M-0.2420Analyst Forecast

Related Companies and Tools


This page (NASDAQ:GRTX) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners